Trial Profile

A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amsacrine; Cytarabine; Cytarabine; Daunorubicin; Idarubicin
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

16 Jul 2012 Biomarkers information updated
01 Jun 2012 Primary endpoints of 'Disease-free-survival' and "overall-survival" have not been met according to results published in the Annals of Hematology.
01 Jun 2012 Final results of the consolidation therapy phase published in the Annals of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com